Bas W.G. van Rhijn, M.D., Ph.D., F.E.B.U.*
|
|
- Vivian Kelley
- 6 years ago
- Views:
Transcription
1 Urologic Oncology: Seminars and Original Investigations 30 (2012) Seminar article Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer Bas W.G. van Rhijn, M.D., Ph.D., F.E.B.U.* Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands Abstract Non-muscle-invasive (NMI) bladder cancer (BC) is a chronic disease with varying oncologic outcomes requiring frequent follow-up and repeated treatments. Recurrence (in up to 80%) is the main problem for pta NMI-BC patients, whereas progression (in up to 45%) is the main threat in pt1 and carcinoma in situ (CIS) NMI-BC. In a recent European Organization for Research and Treatment of Cancer (EORTC) analysis, multiplicity, tumor-size and prior recurrence rate are the most important variables for recurrence. Tumor grade, stage, and CIS are the most important variables for progression to muscle-invasive (MI)-BC. However, reproducibility of pathologic stage and grade is modest, which is a major concern to clinicians. Molecular markers are promising for predicting clinical outcome of NMI-BC, especially because clinicopathologic variables are not sufficient for individual prediction of prognosis. Several obstacles and opportunities have been linked to molecular markers. The role for molecular markers to predict recurrence seems limited because multifocal disease and incomplete treatment probably are more important for recurrence than the molecular features of a removed tumor. Prediction of progression with molecular markers holds considerable promise. Examples are the combination of immunohistochemical markers, gene expression signatures, and molecular grade (based on FGFR3 mutation status and Ki-67 expression). Nevertheless, the value of molecular markers over clinicopathologic indexes is still being questioned and their clinical use limited. One of the reasons may be that reproducibility of prognostic (clinical and molecular) markers in NMI-BC has been understudied Elsevier Inc. All rights reserved. Keywords: Bladder; Cancer; Stage; Grade; FGFR3; Gene-classifier; Immuno-histochemistry; Molecular grade; Reproducibility; Recurrence; Progression Introduction The global incidence of urinary bladder cancer (BC) was approximately 357,000 cases in 2002 [1]. The highest incidence rates are observed in North-America and Western- Europe [1,2], while the lowest rates are found in the Asian countries (China, Japan, Korea) and central Africa [1,3]. Variation in registration of pta (low-grade) tumors may partly be the cause of these differences [4]. In the USA, it is the fourth most common cancer in men and the tenth in women [2]. Most (75%) BCs are non-muscle-invasive (NMI) at first diagnosis [pta, pt1, carcinoma in situ (CIS)] [5]. In NMI- BC, around 70% present as pta, 20% as pt1, and 10% as CIS lesions [6]. Generally, the prognosis of NMI-BC is good, although 30% 80% will recur and 1% 45% will progress to muscle-invasion (MI) within 5 years [5 9]. * Corresponding author. Tel.: ; fax: address: basvanrhijn@hotmail.com (B.W.G. van Rhijn). Consequently, NMI-BC is a chronic disease with varying oncologic outcomes requiring frequent follow-up and repeated treatments, making the cost per patient from diagnosis to death the highest of all cancers [10,11]. Treatment ranges from transurethral resection (TUR) followed by a single chemotherapy instillation in low-risk NMI-BC, to sometimes re-tur and adjuvant intravesical therapy in intermediate- and high-risk patients, and to (early) cystectomy for (treatment-refractory) high-risk NMI-BC [12]. MI-BC (pt2-pt4) is completely opposite from NMI-BC. If left untreated, it is a deadly disease, usually within a short time frame. Treatment often requires a multidisciplinary approach with extensive surgery, radiotherapy, and chemotherapy as cornerstones [13]. Despite these life altering treatments, the prognosis of MI-BC patients who do not have radiological signs of metastasis at time of diagnosis is still dismal. Roughly half of these patients will develop metastasis and eventually die of their disease [13]. Currently, decision making and prognosis of BC still relies heavily on tumor, node, metastasis (TNM) stage /$ see front matter 2012 Elsevier Inc. All rights reserved.
2 B.W.G. van Rhijn / Urologic Oncology: Seminars and Original Investigations 30 (2012) and pathologic grade [12,13]. However, the reproducibility of pathologic assessments is modest [12 15]. Therefore, intense research efforts are being made to identify and characterize molecular markers for various malignancies. Molecular markers hold considerable promise to predict clinical outcome of NMI-BC. Nevertheless, the value of molecular markers over clinicopathologic indexes is still being questioned and their clinical use limited. This review summarizes the current status of clinicopathologic data and molecular markers for prediction of recurrence and progression of NMI-BC. In addition, reproducibility of pathology and molecular markers [immunohistochemistry, gene signatures, and molecular grade (mg)] are discussed. Prognostic factors recurrence Clinical and pathologic prediction of recurrence Clinical and pathologic factors for NMI-BC recurrence have been studied extensively over the years [5,8,16 21]. Although studies vary in the number of included patients, duration of follow-up, the variables analyzed, and statistical analysis, the most important variables for prediction of NMI-BC recurrence are multiplicity, tumor-size, and prior recurrence rate [8,16 21]. Sylvester reviewed 19 articles, of which most compared various intravesical chemotherapy drugs and regimens [19]. In an attempt to individualize prediction of recurrence, Sylvester et al. [8] calculated the probability of recurrence using data of 2,596 patients who participated in 7 European Organization for Research and Treatment of Cancer (EORTC) trials. Different variables were important for recurrence and progression of NMI-BC. Each variable was assigned a weighted score per endpoint (recurrence or progression). The total score per endpoint was based on 6 variables (i.e., grade, stage, CIS, multiplicity, size, and prior recurrence rate). This risk calculator is available at: The European Association of Urology (EAU) subsequently adopted this system in their guidelines and determined the scores for patients at low, intermediate, and high risk for recurrence [5,8]. Recently, Fernandez-Gomez et al. [21] reported the data on prognostic factors from 4 Club Urológico Español de Tratamiento Oncológico (CUETO) trials, in which 1,062 patients received bacille Calmette- Guerin (BCG). Multiplicity, prior tumor, female gender, and CIS were significant predictors for recurrence in multivariate analysis [21]. Taken together, multiplicity is of utmost importance to predict recurrence. The chances on definitive cure of a patient with primary NMI-BC rely on a high quality TUR, removing all (pre)malignant lesions. Multiple tumors probably have more lesions than we are able to visualize and resect at the TUR. Molecular prediction of recurrence Over the years, a wide variety of markers has been identified and linked to BC prognosis. However, most molecular markers show a relation to grade, stage, and progression and not to recurrence of BC [20,22 24]. Even the recently identified FGFR3 (fibroblast growth factor receptor 3) mutation, which allows selective identification of favorable NMI-BC, did not predict recurrence in 2 studies with more than 200 patients either alone or in combination with other molecular markers [25,26], as multiplicity was the only significant predictor for recurrence in multivariate analysis [25]. For P53, opposite results are found. Shariat et al. [27] found the mutant genotype to be a predictor for recurrence, whereas Moonen et al. [28] found more recurrences in patients with wild type tumors. Both studies had adequate follow-up and included around 100 patients. A combination of multiple biomarkers or analyses of multiple genes may be of interest to identify specific markers (survivin [29], Mcm 2 [30]) or gene classifiers to discern recurrent from nonrecurrent NMI-BC [27,29 31]. However, validation with 404 patients from 5 European countries of the previously published 26-gene signature for recurrence was not successful [32]. The role for molecular markers to predict recurrence seems limited. Multifocal disease and incomplete treatment by TUR may be more important for recurrence of NMI-BC than the molecular features of a removed tumor. Prognostic factors progression Clinical and pathologic prediction of progression As for recurrence, clinical, and pathologic factors for NMI-BC progression have been studied extensively over the years [8,16 21]. Fortunately, progression to MI-BC is not as frequent as recurrence. Nevertheless, 5-year probabilities range from 1% to 45%, depending on prognostic factors [5,8]. In larger series, usually the same patient populations were used to predict recurrence and progression [8,19]. The most important variables for prediction of progression in NMI-BC, however, are CIS, grade 3, and stage T1 and, therefore, very different from the most important ones for recurrence [8,17,19]. Sylvester et al. [8] calculated the probability of progression using the same 2,596 patients who participated in 7 EORTC trials. The weighted score for progression based on the same 6 variables as described in this review was used. The EAU also adopted this system in their guidelines [5]. Scores for patients at low, intermediate and high risk for progression to MI-BC were defined [5,8]. The main limitation of the EORTC risk tables is that most patients were treated by old intravesical chemotherapy regimens. Improvements of intravesical chemotherapy, use of a single chemotherapeutic instillation after TUR, and the increased use of (maintenance) BCG may reduce the pre-
3 520 B.W.G. van Rhijn / Urologic Oncology: Seminars and Original Investigations 30 (2012) dictability of these tables, especially for progression. Fernandez-Gomez et al. [21] reported the data on prognostic factors from 4 CUETO trials, in which 1,062 patients received BCG. A recurrence at first cystoscopy, stage, grade, and prior tumor were the prognostic variables in the multivariate analysis for progression. Concomitant CIS was significant in univariable analysis [21]. Additional aggressive factors, which are rare but may be found in NMI-BC, are micropapillary BC and lymphovascular invasion (LVI). Micropapillary NMI-BC is BCG-resistant, and two-thirds of patients NMI-BC progressed to MI [33]. If LVI is present in an NMI-BC specimen at TUR, it indicates understaging and possible lymph-node involvement [34]. Moreover, these authors reported LVI in 9% of their TURs as opposed to 36% of their matched cystectomy specimens [34]. The decision to perform a radical cystectomy for highrisk NMI-BC remains a major challenge for urologists because a randomized comparison between immediate cystectomy and first-line conservative management is not available [12]. Moreover, prognostic factors as outlined above are not conclusive for individual prediction in patients with (high-risk) NMI-BC and, consequently, frequent follow-up with cystoscopy is required [5,8,12,25,35]. Molecular prediction of progression The important pathologic variables for prediction of progression in NMI-BC are CIS, grade 3, and stage T1. These factors reflect the biological aggressiveness of the disease and are associated with the high risk NMI-BC phenotype [5,8,19]. Molecular alterations are often linked to these high-risk pathologic features and not to multiplicity and size, which are clinical variables and more important for recurrence. A wide variety of molecular markers (oncogenes, tumor suppressor genes, cell cycle regulators, epigenetic changes, proliferation antigens, cell adhesion molecules, chromosomal alterations, and signaling proteins, etc.) has been investigated for a better assessment of NMI-BC prognosis [20,22,24,25,35 37]. Some of these markers have shown to be associated with biological aggressive disease and hold promise to predict progression in NMI-BC [20,22,24,25,37]. In this review, some crucial developments will be highlighted. p53 is the most frequently investigated marker to predict progression [25,27,28,38]. Most, but not all, studies found that a p53 mutation or p53 overexpression is associated with progression. The number of patients and methods of analysis cause the discrepancies between studies [38]. Two genetic events (loss of parts of chromosome 9 and FGFR3 mutations) in NMI-BC are both frequent and present in early NMI-BC. Loss of heterozygosity of chromosome 9 has been found in up to 60% of cases [24,36,37]. However, no association with clinical parameters or progression has been found [24,37]. Conversely, the FGFR3 mutation has been found to be a selective marker for favorable disease in several reports [25,26,35,39]. In ptag1, MOLECULAR AND CLINICAL PATHWAYS OF BLADDER CANCER Normal Urothelium FGFR3 mutation p53 Ki-67 pta/1 G1/2 pta/1 G2/3 CIS Progression pt2 G2/3 pt2 G3 INCREASING NUMBER OF GENETIC EVENTS Metastasis Fig. 1. Simplified two-pathway model for disease pathogenesis of BC. This figure shows the combination of molecular and pathologic data in nonmuscle-invasive BC. Arrow thickness is indicative for the percentage of tumors. The FGFR3 mutation is largely responsible for the favorable molecular pathway in NMI-BC. Among many others, P53 and Ki-67 overexpression are examples of unfavorable NMI-BC. Molecular alterations, not included in the figure in the interest of clarity, are represented by the bottom arrow. FGFR3 fibroblast growth factor receptor 3 gene; mt mutation; 1 elevated expression (Ki-67, p53); CIS carcinoma in situ. 88% had a mutation as opposed to 19% of pt1g3 cases [25]. Moreover, in several independent studies, the FGFR3 mutation protected against progression [25,26,35,39]. This led to the proposal of the FGFR3 mutation as the genetic event responsible for the favorable pathway in BC (Fig. 1) [25]. Furthermore, based on FGFR3 mutation status and the expression of the proliferation marker Ki-67, molecular grade (mg1-3) was introduced as a highly reproducible and prognostic tool in BC progression. The first prospective data confirmed the prognostic value of molecular grade (mg) for progression [26]. Moreover, in a study with long-term (median; 8.6 years) follow-up, the addition of mg to the multivariable model for progression significantly increased its predictive accuracy and mg provided valuable prognostic information next to the EORTC risk-scores for progression [35]. The story of p53 has taught us that a combination of molecular markers is necessary to predict progression [38]. mg as discussed above is an example of this. Another example is the differential expression of multiple immunohistochemical markers from 1 tissue sample using a tissue micro array (TMA). Shariat et al. [27] investigated p53, prb, P21, and P27 and found that the number of altered markers was independently associated with an increased risk of progression. The technique is easy, its analysis has been automated, is possible in any pathology laboratory, and enhances prediction of progression [27,40]. Another example of combining genetic information is the construction of a gene classifier using microarrays [31]. This approach has the potential for individual prediction of prognosis. In an international validation study, which is currently the largest study on gene-expression microarrays, 2 classifiers, 1 based on 52 genes and another on 88 genes, were significant in multivariate analysis for progression [32]. Although these gene classifiers enhanced prediction of progression next to clinicopathologic indexes, sensitivity and specificity to predict progression were both only 66%. Hence, a gene classifier on its own is not enough to predict progression in individual cases.
4 B.W.G. van Rhijn / Urologic Oncology: Seminars and Original Investigations 30 (2012) Prospective data using well-defined patient cohorts and endpoints will give us valuable information on mg [25,35] and the (tissue/gene) microarray technologies [27,31,32,40] in the future. In addition, more work is needed on reproducibility, easy access to these technologies, and simplification and combination of methods. Until then, the value of molecular markers over traditional histopathology is not clear and, therefore, these markers are currently not used in clinical decision making. Reproducibility Observer variability and prognosis in pathology Reproducibility of pathologic assessment has not been studied as extensively as clinicopathologic prediction of recurrence and progression [12]. Nevertheless, reproducibility is of utmost importance to compare clinical results between institutes and also if we want to individualize the prognostic value of NMI-BC grade and stage. The largest study on stage review was published in 2000 [15]. Local pathology and review pathology were compared in 1,400 patients who participated in 5 EORTC trials. Although agreement between pathologists varied from 36% to 90%, differences in prognosis were slight. The authors recommended pathology review in high-risk NMI-BC. This conclusion was confirmed by a study with 164 T1 NMI-BC patients treated with BCG whose original slides were reviewed [41]. Close to 20% of T1 tumors were up-staged or down-staged, and the reviewed stage strongly predicted patient s prognosis [41]. Hence, pathology review in the high-risk NMI-BC category identifies patients with different prognoses who may benefit from other treatment strategies than BCG. Pathologic grade carries significant prognostic information, especially for prediction of progression [5 9,12 21]. However, its poor reproducibility is a recognized problem and a major concern. Grade assessment (WHO 1973) varied from 42% to 73% between local and review pathologists in the 5 EORTC studies mentioned above [15]. A new classification system for grade was adopted by the WHO in 2004 [12]. Next to high observer variability, the main reasons to propose a new system were the lack of clear definitions for the three WHO 1973 grades and the high percentage of NMI-BC classified as G2 (the default diagnosis) [12]. Although the new system contains detailed histologic criteria to decrease observer variability, direct comparison of both classification systems for grade did not result in a better prediction of progression and/or better reproducibility [12,14]. The main criticism of the new system is that it has been accepted despite lack of clinical evidence and proper studies with long-term follow-up to assess its reproducibility and prognostic value compared with the old WHO 1973 system [12]. Therefore, the AUA and EAU guidelines advocate the use of both systems until the 2004 system has been properly validated [12,16]. However, the advantage of the new system over the WHO 1973 system will probably not be large as interobserver variability remains high in both systems. Recently, the mean grade of a pathologist was found to be constant for 1 pathologist but highly variable between pathologists (up to 0.7 grade), irrespective of the classification system used [14]. In this study with 173 NMI-BC cases, the mean-grades for the WHO 2004 system were grades higher than those of WHO Mean grade distinguished low- and high graders among the pathologists, and this knowledge was strongly linked with the risk of progression for each grade category [14]. This new mean grade concept allows a better assessment of the prognostic value of grading. Mean grade has the potential of becoming a tool for quality assurance in pathology and clinical trials [14]. Stage and grade are the gold standards on which treatment decisions in NMI-BC are based. The poor reproducibility of pathologic stage and grade is a recognized problem and a major concern for clinicians. It is probably the main reason that individual decision-making based on grade and stage is troublesome in individual cases. Reproducibility of molecular markers Studies on reproducibility of molecular markers are rare. Hereunder, some aspects of reproducibility of immunohistochemistry, gene signatures, and molecular grade (mg) for NMI-BC are discussed. The National Cancer Institute (NCI) conducted a very well-designed study on the reproducibility of p53 immunohistochemistry [42]. Fifty high-grade, primary BCs were subjected to several sources of variability (i.e., the scorer, the staining laboratory, and another tumor-block). The percentage agreement ranged from 83% (2 scorers, 2 slides, 2 staining laboratories) to 95% (1 scorer, 2 slides, 1 staining laboratory). In another study, the percentage agreement (2 scorers, 1 slides, 1 staining laboratory) for Ki-67, p53, and P27 were 91%, 88%, and 85%, respectively [25]. These values are higher than the percentages of agreement for pathologic grade but it should be noted that immunohistochemistry is either positive or negative (2-tier system) and pathologic grade usually is a 3-tier system. In the new WHO 2004 classification system, for grade the first 2 categories are sometimes lumped together, resulting in a 2-tier system. Using such an approach, the percentages of agreement for pathologic grade ranged from 68% to 87% (4 pathologists, 1 slide, 1 laboratory). These values come close to but do not completely reach the reproducibility of immunohistochemistry. Several groups have constructed a gene classifier using microarrays to predict clinical outcome [31,32,43,44]. The classification performances show very similar accuracies to predict NMI-BC progression but the studies show only little overlap in the identified genes that are part of the classifier [31,32,43,44]. Some explanations for this phenomenon may
5 522 B.W.G. van Rhijn / Urologic Oncology: Seminars and Original Investigations 30 (2012) include heterogeneity between the analyzed tumors, poor reproducibility of this method, and/or a cutoff value issue when scaling down from expression profiles of 20,000 genes to less than 100 genes to construct a gene classifier. The main issue that remains is which genes to choose in a classifier to predict a certain clinical endpoint. Molecular grade (mg), based on FGFR3 mutation status and Ki-67 expression, has been proposed as an alternative to predict progression [25,35]. A recent study was the first to compare the reproducibility of pathologic grading and mg on the same series of patients [35]. The reproducibility of mg was almost perfect ( ; 0.76), whereas reproducibility for pathologic grade was only fair to substantial ( : ) [35]. Taken together, mg (composed of 3 mg) proved more reproducible than pathologic grade assessment, making it a reliable and robust tool to assess progression in NMI-BC. The reproducibility of molecular markers in NMI-BC is an understudied subject, which deserves more attention if molecular markers are to become important in clinical practice. Conclusions Prognosis of NMI-BC relies heavily on clinical variables (multiplicity, size, and prior recurrence rate) to predict recurrence, and pathologic variables (TNM-stage, grade, and CIS) to predict progression. The role for molecular markers to predict recurrence seems limited. Prediction of progression with molecular markers holds considerable promise. Reproducibility is understudied compared with prognostic analyses for recurrence and progression of NMI-BC. Nevertheless, it is highly important. If the gold standard (stage, grade) is not reproducible, prognostic analyses may be biased. Moreover, the fair to substantial reproducibility of pathology in NMI-BC may be a critical obstacle for the introduction of molecular markers in clinical practice. Several opportunities have recently been identified. First, knowledge of the pathologist s mean grade may be a step forward for quality control in pathology and clinical trials. Second, prospective data using well-defined patient cohorts and endpoints will give us valuable information on mg and (tissue/gene) microarray technologies in the near future. The reproducibility of prognostic (clinical and molecular) markers in NMI-BC has been understudied and deserves more attention. References [1] Ferlay J, Bray F, Pisani P, et al. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase, version 1.0; 2002 No. 5. IARCPress, Lyon, Available at: Accessed September 15, [2] Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;2008: [3] Colombel M, Soloway M, Akaza H, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 2008;7: [4] Wu X, Ros MM, Gu J, et al. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008;102: [5] Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54: [6] Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 2005;66(Suppl 6A):4 34. [7] Kiemeney LA, Witjes JA, Verbeek AL, et al. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 1993;67: [8] Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49: [9] Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178: [10] Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer. Pharmacoeconomics 2003;21: [11] Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33: [12] Van Rhijn BWG, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009;56: [13] Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374: [14] van Rhijn BWG, van Leenders GJLH, Ooms ECM, et al. The pathologist s mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 2010;57: [15] Van der Meijden A, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 2000;164: [16] Zieger K, Wolf H, Olsen PR, et al. Long-term follow-up of noninvasive bladder tumours (stage Ta): Recurrence and progression. BJU Int 2000;85: [17] Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73 8. [18] Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164: [19] Sylvester RJ. Natural history, Recurrence and progression in superficial bladder cancer. TSW. Urology 2006;1: [20] Kurth KH, Sylvester RJ. Prognostic factors in non-muscle-invasive bladder tumors. I: Clinical prognostic factors: A review of the experience of the EORTC Genito-urinary group. II: Biologic prognostic markers. Eur Urol 2007;6(Suppl): [21] Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: Multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53: [22] Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 1998;160: [23] Duggan BJ, McKnight JJ, Williamson KE, et al. The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 2003;9: [24] Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese. Carcinogenesis 2006;27: [25] van Rhijn BWG, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:
6 B.W.G. van Rhijn / Urologic Oncology: Seminars and Original Investigations 30 (2012) [26] Burger M, van der Aa MN, van Oers JM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A prospective study. Eur Urol 2008;54: [27] Shariat SF, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177: [28] Moonen PM, van Balken-Ory B, Kiemeney LA, et al. Prognostic value of P53 for high risk superficial bladder cancer with long-term follow-up. J Urol 2007;177:80 3. [29] Schultz IJ, Wester K, Straatman H, et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007;51: [30] Burger M, Denzinger S, Hartmann A, et al. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer 2007;96: [31] Dyrskjøt L, Thykjaer T, Kruhøffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90 6. [32] Dyrskjøt L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 2007;13: [33] Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006;175: [34] Kunju LP, You L, Zhang Y, et al. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 2008;180: [35] van Rhijn BWG, Zuiverloon TCM, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010; 58: [36] Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54: [37] Karam JA, Shariat SF, Hsieh JT, et al. Genomics: A preview of genomic medicine. BJU Int 2008;102: [38] Schmitz-Dräger BJ, Goebell PJ, Ebert T, et al. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;38: [39] Hernández S, López-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas. J Clin Oncol 2006;24: [40] Shariat SF, Zlotta AR, Ashfaq R, et al. Cooperative effect of cellcycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20: [41] van Rhijn BWG, van der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pt1 bladder cancer. BJU Int 2010;106: [42] McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 2000; 6: [43] Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11: [44] Lindgren D, Liedberg G, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:
Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationUrological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi
Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title High-risk nonmuscle invasive bladder cancer: Definition and epidemiology Permalink https://escholarship.org/uc/item/11p2k07q Journal Current
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationTHE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER
THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean
More informationMaintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive
Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationRecurrence and Progression of Disease in Non Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
EUROPEAN UROLOGY 56 (2009) 430 442 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Bladder Cancer Recurrence and Progression of Disease in Non Muscle-Invasive
More informationThe value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice
48 Original Paper UROLOGICAL ONCOLOGY The value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice Rafał Walczak, Krzysztof Bar 2, Janusz Walczak Department
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationKyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang
www.kjurology.org DOI:.4/kju..5..65 Urological Oncology The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after
More informationEfficient and Effective Use of Exfoliative Markers
Innovations in Urologic Oncology: Bladder Cancer Efficient and Effective Use of Exfoliative Markers Jared M Whitson, MD April 9 th, 2010, CA URINARY TUMOR MARKERS Future Directions Urinary Tumor Markers
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationContemporary management of high-grade T1 bladder cancer Arnulf Stenzl
Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Dep. of Urology, Eberhard-Karls University, Tuebingen, Germany Treatment options in HG T1 BCa TUR-BT Primary and second resection (T0-status)
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationMolecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications
& 2015 USCAP, Inc. All rights reserved 0893-3952/15 $32.00 695 Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications Bas WG van
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationOriginal Article APMC-276
Original Article APMC-276 The Clinical Value of Immediate Second Transurethral Resection in Patients with High Grade Non-Muscle Inasive Bladder Cancer (HG-NMIBC) Syed Saleem Abbas Jafri, Zafar Iqbal Khan
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
2885 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(15): 2885-2891. doi: 10.7150/jca.20003 Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT:
More informationPatient Risk Profiles: Prognostic Factors of Recurrence and Progression
european urology supplements 5 (2006) 648 653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Patient Risk Profiles: Prognostic Factors of Recurrence and Progression
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence
More informationComparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer
EUROPEAN UROLOGY 63 (2013) 145 154 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Urothelial Cancer Editorial by J. Alfred Witjes on pp. 155 157 of this
More informationPrognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy
European Urology European Urology 45 (2004) 292 296 Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy Barthold Ph. Schrier a, Maarten
More informationA rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases
MOLECULAR AND CLINICAL ONCOLOGY 8: 785-790, 2018 A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases MASAKAZU AKITAKE 1,
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationFrequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience
2nd Annual Surgical Meeting 2016 S-125 UROLOGY ORIGINAL ARTICLE Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience Muhammad Farhan, Syed
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More informationUpdate on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically
More informationIntravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology
More informationThe Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study
The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary
More informationUpdate on bladder cancer diagnosis and management
7 Update on bladder cancer diagnosis and management RICHARD T. BRYAN Although the basis of the diagnosis and management of urothelial bladder cancer has remained unchanged for two decades or more, there
More informationNon-muscle invasive bladder cancer: Are epicrises the Bermuda Triangle of information transfer?
245 O R I G I N A L P A P E R UROLOGICAL ONCOLOGY Non-muscle invasive bladder cancer: Are epicrises the Bermuda Triangle of information transfer? Steffen Lebentrau 1, Matthias May 2, Anne-Kathrin Wick
More informationSUPERFICIAL BLADDER CANCER MANAGEMENT
A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored
More informationReview Article. Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
Review Article Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer Ashish M. Kamat,*, J. Alfred Witjes, Maurizio Brausi, Mark Soloway,jj Donald Lamm, Raj Persad, Roger
More informationMixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome
DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti
More informationImproving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer
european urology supplements 5 (2006) 654 659 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression
More informationIntravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationHow Many Diseases in Carcinoma in situ?
How Many Diseases in Carcinoma in situ? Eva Compérat La Pitié Salpêtrière Assistance Publique Université Pierre et Marie Curie, Paris VI Carcinogenesis of Bladder Cancer (BC) BC is a panurothelial disease
More informationLong term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression
Kobayashi et al. BMC Urology 2014, 14:5 RESEARCH ARTICLE Open Access Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening
More informationPathology review impacts clinical management of patients with T1 T2 bladder cancer
Original research Pathology review impacts clinical management of patients with T1 T2 bladder cancer Samer L. Traboulsi, MD 1 ; Fadi Brimo, MD, FRCP(C) 2 ; Yutong Yang, MD 2 ; Chelsea Maedler, MD 2 ; Noémie
More informationThe outcome of non-muscle invasive urinary bladder tumour at Makassed General Hospital
Makassed General Hospital The outcome of non-muscle invasive urinary bladder tumour at Makassed General Hospital Imad El Hajjar Department of surgery, Urology division Introduction Most common malignancy
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More informationInfluence of stage discrepancy on outcome in. in patients treated with radical cystectomy.
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
More informationProspective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
Original Article p53 AS A PROGNOSTIC MARKER IN BLADDER CANCER DALBAGNI et al. There have been several published reports that p53 is a useful prognostic marker for progression and survival in bladder cancer.
More informationNext-generation sequencing in non-muscle-invasive bladder cancer a step towards personalized medicine for a superficial bladder tumor
Editorial Next-generation sequencing in non-muscle-invasive bladder cancer a step towards personalized medicine for a superficial bladder tumor Andrew Butterfield, Sumati Gupta Huntsman Cancer Institute,
More informationNew and contemporary markers of prognosis in nonmuscle invasive urothelial cancer
Review Article Korean J Urol 5;56:55-564. http://dx.doi.org/.4/kju.5.56.8.55 pissn 5-677 eissn 5-6745 New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer M Hammad Ather, Syed
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationNatural History, Recurrence, and Progression in Superficial Bladder Cancer
Review Article Superficial Bladder Cancer TheScientificWorldJOURNAL (2006) 6, 2617 2625 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2006.404 Natural History, Recurrence, and Progression in Superficial
More informationEmerging Prognostic Biomarkers in Urothelial Carcinoma
Emerging Prognostic Biomarkers in Urothelial Carcinoma George J. Netto, M.D. Departments of Pathology, Oncology & Urology Johns Hopkins University Baltimore, MD USA Overview Current Clinicopathologic Prognostic
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationImmunohistochemical determinations in evaluating the prognostic in patient with urinary bladder tumors
Romanian Journal of Morphology and Embryology 2006, 47(2):175 179 ORIGINAL PAPER Immunohistochemical determinations in evaluating the prognostic in patient with urinary bladder tumors E. TRAŞCĂ 1), R.
More informationKeishiro Fukumoto 1, Eiji Kikuchi 1*, Shuji Mikami 2, Akira Miyajima 1 and Mototsugu Oya 1
Fukumoto et al. BMC Urology (2016) 16:5 DOI 10.1186/s12894-016-0122-1 RESEARCH ARTICLE Open Access Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationRole of Re-Resection in Non Muscle-Invasive Bladder Cancer
Review Special Issue: Bladder Cancer TheScientificWorldJOURNAL (2011) 11, 283 288 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2011.29 Role of Re-Resection in Non Muscle-Invasive Bladder Cancer Harry W.
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationCitation for published version (APA): Cauberg, E. C. C. (2011). Advancements in diagnostic imaging for urothelial carcinoma.
UvA-DARE (Digital Academic Repository) Advancements in diagnostic imaging for urothelial carcinoma Cauberg, E.C.C. Link to publication Citation for published version (APA): Cauberg, E. C. C. (2011). Advancements
More informationGenerated by Foxit PDF Creator Foxit Software For evaluation only.
Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series Vol. (3) No. (٣) 28 27 2 28 2 T3 T4 T2 T1 Ta TUR G3 G2 G1 * ٩ 27 2 Tishreen University Journal for Research and
More informationCritical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC
Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No
More informationThe Role of Bacillus Calmette-Guérin in the Treatment of Non Muscle-Invasive Bladder Cancer
EUROPEAN UROLOGY 57 (2010) 410 429 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Bladder Cancer The Role of Bacillus Calmette-Guérin in the Treatment
More informationRisk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours
Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours Moniek M. Vedder 1, Mirari Márquez 2, Esther W. de Bekker-Grob
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationManagement of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS
Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationPhase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer
Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer K. Hendricksen,* E. B. Cornel, T. M. de Reijke, H. C. Arentsen, S. Chawla and J. A. Witjes
More informationImpact of the Ki-67 labeling index and p53 expression status on disease-free survival in pt1 urothelial carcinoma of the bladder
Original Article Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pt1 urothelial carcinoma of the bladder Malte W. Vetterlein 1 *, Julia Roschinski 1 *, Philipp
More informationPharmacologyonline 3: (2006)
INTRAVESICAL MISTLETOE EXTRACT FOR ADJUVANT TREATMENT OF SUPERFICIAL URINARY BLADDER CANCER P. Bühler 1, C. Leiber 1, M. Lucht 2, P. Wolf 1, U. Wetterauer 1, U. Elsässer-Beile 1 1 Department of Urology,
More informationRESEARCH ARTICLE. Ali Koyuncuer. Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Histopathologic Evolution of Urothelial Carcinoma Recurrence in Transurethral Resection of the Urinary Bladder:35 Consecutive Cases And Literature Review Abstract Background: Urothelial
More informationRadiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer
Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationBJUI. Invasive T1 bladder cancer: indications and rationale for radical cystectomy
2008 The Authors; Journal compilation 2008 BJU International Mini-review Article INVASIVE T1 BLADDER CANCER: INDICATIONS AND RATIONALE FOR RADICAL CYSTECTOMY STEIN and PENSON BJUI BJU INTERNATIONAL Invasive
More informationNeo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder
Annals of Oncology : -5. 999. 999 Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationNomograms for Bladder Cancer
european urology 54 (2008) 41 53 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer Nomograms for Bladder Cancer Shahrokh F. Shariat a, *, Vitaly Margulis
More informationObjectives. Results. Patients and Methods. Conclusions. associated percentages were used to analyse treatment variables.
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international
More informationManagement of Superficial Bladder Cancer Douglas S. Scherr, M.D.
Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationOriginal Article. Abstract
Original Article Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscleinvasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
More informationMaintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer
710 Maintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer How Much Is Enough? Marc Decobert, PhD Helène LaRue, PhD François Harel, MSc François Meyer, MD Yves Fradet, MD Louis
More informationIntravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure
Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H.
More informationCytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis
https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali
More informationT1HG Bladder Cancer What is the Best Therapy?
T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction
More informationSecond transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study
Japanese Journal of Endourology(2018)31:108-112 Original Article CJapanese Society of Endourology 2018 Tetsuya Shindo Naotaka Nishiyama Naoya Masumori Second transurethral resection against Ta high grade
More informationA Review of Outcomes for Stage Ta Bladder Tumors
AJCP /ORIGINAL ARTICLE A Review of Outcomes for Stage Ta Bladder Tumors Robin T. Vollmer, MD From the VA and Duke University Medical Centers, Durham, NC. Key Words: Urothelial tumors; Tumor grade; Outcomes;
More information/05/ /0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/05/1741-0086/0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000162059.64886.1c BACILLUS CALMETTE-GUERIN
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationIncidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy
Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy Jacob T. Ark*, Kirk A. Keegan*, Daniel A. Barocas*, Todd M. Morgan*, Matthew J.
More informationModelling the recurrence of bladder cancer
Modelling the recurrence of bladder cancer Gregorio Rubio 1, Cristina Santamaría 1, Belén García 1, and José Luis Pontones 2 1 Matemática multidisciplinar Universidad Politécnica Valencia (Spain) (e-mail:
More informationClinical significance of random bladder biopsy in primary T1 bladder cancer
MOLECULAR AND CLINICAL ONCOLOGY 8: 665-670, 2018 Clinical significance of random bladder biopsy in primary T1 bladder cancer MASAFUMI OTSUKA 1, SATORU TAGUCHI 1, TOHRU NAKAGAWA 1, TEPPEI MORIKAWA 2, SHIGEKATSU
More informationELISABETH FRANSEN VAN DE PUTTE
ELISABETH FRANSEN VAN DE PUTTE PROGNOSIS AND TREATMENT OF INVASIVE BLADDER CANCER Prognose en behandeling van het invasieve blaascarcinoom (met een samenvatting in het Nederlands) Prognosis and treatment
More informationThe Characteristics of Recurrent Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy without Bladder Cuff Excision
Original Article http://dx.doi.org/10.3349/ymj.2015.56.2.375 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 56(2):375-381, 2015 The Characteristics of Recurrent Upper Tract Urothelial Carcinoma after
More information